Strategies to optimize collection of hematopoietic stem cells in patients with mantle cell lymphoma receiving hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate (Hyper-CVAD) chemotherapy

Mantle cell lymphoma (MCL) has aptly been described as a lymphoma with features of ‘the worst of both worlds,’ being both incurable and aggressive, historically with a median survival of 3–5 years ...